Karyotype in acute mybloblastic leukemia (AML): Prognostic significance in bone marrow transplantation in first remission (CR1) a study from Ike scttt leukemia working-party of the European Cooperative Group foe Bknd and Marrow Transplanlaobi (EBMT) NC

Forin M. Labonin; F. Frassoni; H. G. Prenitice; J. Y. Caba; J. Reiffers; M. Boogaerts; G. Bandini; B. Lowernberg; M. Attal; A. Ferrant

Karyotype in acute mybloblastic leukemia (AML): Prognostic significance in bone marrow transplantation in first remission (CR1) a study from Ike scttt leukemia working-party of the European Cooperative Group foe Bknd and Marrow Transplanlaobi (EBMT) NC

Forin M. Labonin, F. Frassoni, H. G. Prenitice, J. Y. Caba, J. Reiffers, M. Boogaerts, G. Bandini, B. Lowernberg, M. Attal, A. Ferrant

Istituto "Giannina Gaslini"

Research output: Contribution to journal › Article › peer-review

Abstract

The cylojoielic due of 999 AML pitocs who lud BMT in CR1 hive been ulysed. The karyotypes atiu45), K1S;17) (n-80), 1(831) (->). Ita 5 nd/oi 7 (..50). bu llq (.-33), pieudodkiloid (n.72), hypodiploid (1.24), hyperdipbid (nrf6), or diploU (n-bi llq. pnudodinloidy, hyperdiploidy or with normal kuyotype did not differ. This group of pUieMa hid bead survivil, rorutlil dunliog nd kukemil free survival (LFS) probability than the group of patients with abn 5 and/or 7 or hypodiptady (survival: 0.54 vs 0.23, p-0.00005; remisaioB duration: 0.62 vs 0.21, p-0-000001; LPS: 0.50 vs 0.17,p-0.000008). The outcomes of AUoBMT and ABMT patients with unfavorable cylogenetics were simuar. When conparkl AUoBMT and ABMT in patients with favorable cytogenelio, AUoBMT was of benefit for remisBR duration (p

Original language	English
Pages (from-to)	1124
Number of pages	1
Journal	Experimental Hematology
Volume	24
Issue number	9
Publication status	Published - 1996

ASJC Scopus subject areas

Cancer Research
Cell Biology
Genetics
Hematology
Oncology
Transplantation

Access to Document

Fingerprint Dive into the research topics of 'Karyotype in acute mybloblastic leukemia (AML): Prognostic significance in bone marrow transplantation in first remission (CR1) a study from Ike scttt leukemia working-party of the European Cooperative Group foe Bknd and Marrow Transplanlaobi (EBMT) NC'. Together they form a unique fingerprint.

Cite this

Labonin, F. M., Frassoni, F., Prenitice, H. G., Caba, J. Y., Reiffers, J., Boogaerts, M., Bandini, G., Lowernberg, B., Attal, M., & Ferrant, A. (1996). Karyotype in acute mybloblastic leukemia (AML): Prognostic significance in bone marrow transplantation in first remission (CR1) a study from Ike scttt leukemia working-party of the European Cooperative Group foe Bknd and Marrow Transplanlaobi (EBMT) NC. Experimental Hematology, 24(9), 1124.

Karyotype in acute mybloblastic leukemia (AML) : Prognostic significance in bone marrow transplantation in first remission (CR1) a study from Ike scttt leukemia working-party of the European Cooperative Group foe Bknd and Marrow Transplanlaobi (EBMT) NC. / Labonin, Forin M.; Frassoni, F.; Prenitice, H. G.; Caba, J. Y.; Reiffers, J.; Boogaerts, M.; Bandini, G.; Lowernberg, B.; Attal, M.; Ferrant, A.

In: Experimental Hematology, Vol. 24, No. 9, 1996, p. 1124.

Research output: Contribution to journal › Article › peer-review

Labonin, FM, Frassoni, F, Prenitice, HG, Caba, JY, Reiffers, J, Boogaerts, M, Bandini, G, Lowernberg, B, Attal, M & Ferrant, A 1996, 'Karyotype in acute mybloblastic leukemia (AML): Prognostic significance in bone marrow transplantation in first remission (CR1) a study from Ike scttt leukemia working-party of the European Cooperative Group foe Bknd and Marrow Transplanlaobi (EBMT) NC', Experimental Hematology, vol. 24, no. 9, pp. 1124.

Labonin FM, Frassoni F, Prenitice HG, Caba JY, Reiffers J, Boogaerts M et al. Karyotype in acute mybloblastic leukemia (AML): Prognostic significance in bone marrow transplantation in first remission (CR1) a study from Ike scttt leukemia working-party of the European Cooperative Group foe Bknd and Marrow Transplanlaobi (EBMT) NC. Experimental Hematology. 1996;24(9):1124.

Labonin, Forin M. ; Frassoni, F. ; Prenitice, H. G. ; Caba, J. Y. ; Reiffers, J. ; Boogaerts, M. ; Bandini, G. ; Lowernberg, B. ; Attal, M. ; Ferrant, A. / Karyotype in acute mybloblastic leukemia (AML) : Prognostic significance in bone marrow transplantation in first remission (CR1) a study from Ike scttt leukemia working-party of the European Cooperative Group foe Bknd and Marrow Transplanlaobi (EBMT) NC. In: Experimental Hematology. 1996 ; Vol. 24, No. 9. pp. 1124.

@article{6f44a7d393184ceb91b1e85aa661872b,

title = "Karyotype in acute mybloblastic leukemia (AML): Prognostic significance in bone marrow transplantation in first remission (CR1) a study from Ike scttt leukemia working-party of the European Cooperative Group foe Bknd and Marrow Transplanlaobi (EBMT) NC",

abstract = "The cylojoielic due of 999 AML pitocs who lud BMT in CR1 hive been ulysed. The karyotypes atiu45), K1S;17) (n-80), 1(831) (->). Ita 5 nd/oi 7 (..50). bu llq (.-33), pieudodkiloid (n.72), hypodiploid (1.24), hyperdipbid (nrf6), or diploU (n-bi llq. pnudodinloidy, hyperdiploidy or with normal kuyotype did not differ. This group of pUieMa hid bead survivil, rorutlil dunliog nd kukemil free survival (LFS) probability than the group of patients with abn 5 and/or 7 or hypodiptady (survival: 0.54 vs 0.23, p-0.00005; remisaioB duration: 0.62 vs 0.21, p-0-000001; LPS: 0.50 vs 0.17,p-0.000008). The outcomes of AUoBMT and ABMT patients with unfavorable cylogenetics were simuar. When conparkl AUoBMT and ABMT in patients with favorable cytogenelio, AUoBMT was of benefit for remisBR duration (p",

author = "Labonin, {Forin M.} and F. Frassoni and Prenitice, {H. G.} and Caba, {J. Y.} and J. Reiffers and M. Boogaerts and G. Bandini and B. Lowernberg and M. Attal and A. Ferrant",

year = "1996",

language = "English",

volume = "24",

pages = "1124",

journal = "Experimental Hematology",

issn = "0301-472X",

publisher = "Elsevier Inc.",

number = "9",

}

TY - JOUR

T1 - Karyotype in acute mybloblastic leukemia (AML)

T2 - Prognostic significance in bone marrow transplantation in first remission (CR1) a study from Ike scttt leukemia working-party of the European Cooperative Group foe Bknd and Marrow Transplanlaobi (EBMT) NC

AU - Labonin, Forin M.

AU - Frassoni, F.

AU - Prenitice, H. G.

AU - Caba, J. Y.

AU - Reiffers, J.

AU - Boogaerts, M.

AU - Bandini, G.

AU - Lowernberg, B.

AU - Attal, M.

AU - Ferrant, A.

PY - 1996

Y1 - 1996

N2 - The cylojoielic due of 999 AML pitocs who lud BMT in CR1 hive been ulysed. The karyotypes atiu45), K1S;17) (n-80), 1(831) (->). Ita 5 nd/oi 7 (..50). bu llq (.-33), pieudodkiloid (n.72), hypodiploid (1.24), hyperdipbid (nrf6), or diploU (n-bi llq. pnudodinloidy, hyperdiploidy or with normal kuyotype did not differ. This group of pUieMa hid bead survivil, rorutlil dunliog nd kukemil free survival (LFS) probability than the group of patients with abn 5 and/or 7 or hypodiptady (survival: 0.54 vs 0.23, p-0.00005; remisaioB duration: 0.62 vs 0.21, p-0-000001; LPS: 0.50 vs 0.17,p-0.000008). The outcomes of AUoBMT and ABMT patients with unfavorable cylogenetics were simuar. When conparkl AUoBMT and ABMT in patients with favorable cytogenelio, AUoBMT was of benefit for remisBR duration (p

AB - The cylojoielic due of 999 AML pitocs who lud BMT in CR1 hive been ulysed. The karyotypes atiu45), K1S;17) (n-80), 1(831) (->). Ita 5 nd/oi 7 (..50). bu llq (.-33), pieudodkiloid (n.72), hypodiploid (1.24), hyperdipbid (nrf6), or diploU (n-bi llq. pnudodinloidy, hyperdiploidy or with normal kuyotype did not differ. This group of pUieMa hid bead survivil, rorutlil dunliog nd kukemil free survival (LFS) probability than the group of patients with abn 5 and/or 7 or hypodiptady (survival: 0.54 vs 0.23, p-0.00005; remisaioB duration: 0.62 vs 0.21, p-0-000001; LPS: 0.50 vs 0.17,p-0.000008). The outcomes of AUoBMT and ABMT patients with unfavorable cylogenetics were simuar. When conparkl AUoBMT and ABMT in patients with favorable cytogenelio, AUoBMT was of benefit for remisBR duration (p

UR - http://www.scopus.com/inward/record.url?scp=33748592563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748592563&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33748592563

VL - 24

SP - 1124

JO - Experimental Hematology

JF - Experimental Hematology

SN - 0301-472X

IS - 9

ER -